Security Snapshot

Kyverna Therapeutics, Inc. - Common Stock, par value $0.00001 per share (KYTX) Institutional Ownership

CUSIP: 501976104

13F Institutional Holders and Ownership History from Q1 2024 to Q1 2026

Latest Period

Q4 2025

Institutions Reporting

99

Shares (Excl. Options)

34,131,760

Price

$9.40

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place.

Create free account to save this page Review latest holder period
Type / Class
Equity / Common Stock, par value $0.00001 per share
Symbol
KYTX on Nasdaq
Shares outstanding
56,833,213
Price per share
$8.63
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
34,131,760
Total reported value
$320,775,226
% of total 13F portfolios
0%
Share change
+11,302,004
Value change
+$111,162,333
Number of holders
99
Price from insider filings
$8.63
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Quick Takeaways

  • KYTX - Kyverna Therapeutics, Inc. - Common Stock, par value $0.00001 per share is tracked under CUSIP 501976104.
  • 99 institutions reported positions in Q4 2025.
  • 4 significant owners is listed from Schedule 13D/13G reporting.

What Changed

  • Holder count moved from 99 to 7 between Q4 2025 and Q1 2026.
  • Reported value moved from $320,775,226 to $1,484,171.

Why This Matters

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Source Evidence

Source: SEC Form 13F

Latest holder context comes from 99 institutions filings for Q4 2025.

Open SEC Evidence

Investment Quick Answers

What is CUSIP 501976104?
CUSIP 501976104 identifies KYTX - Kyverna Therapeutics, Inc. - Common Stock, par value $0.00001 per share in SEC 13F datasets.

Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.

Significant Owners of Kyverna Therapeutics, Inc. - Common Stock, par value $0.00001 per share (KYTX) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Westlake BioPartners Fund I, L.P. 7.8% $43,778,216 4,657,257 Dr. Beth C. Seidenberg ("Seidenberg") 31 Dec 2025
Northpond Ventures III, LP 6.1% $28,531,978 3,466,826 Michael P. Rubin 31 Dec 2025
Bain Capital Life Sciences Opportunities III, LP 5.4% $25,595,300 3,110,000 Bain Capital Life Sciences Opportunities III, LP 31 Dec 2025
GordonMD Global Investments LP 7% $23,275,071 3,058,485 GordonMD Global Investments LP 13 Nov 2025

As of 31 Dec 2025, 99 institutional investors reported holding 34,131,760 shares of Kyverna Therapeutics, Inc. - Common Stock, par value $0.00001 per share (KYTX). This represents 60% of the company’s total 56,833,213 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Kyverna Therapeutics, Inc. - Common Stock, par value $0.00001 per share (KYTX) together control 52% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
GordonMD Global Investments LP 7.7% 4,391,818 0% 30% $41,283,089
GILEAD SCIENCES, INC. 7.3% 4,126,119 0% 2% $38,785,519
Bain Capital Life Sciences Investors, LLC 5.5% 3,110,000 -7.7% 2.2% $29,234,000
DEERFIELD MANAGEMENT COMPANY, L.P. 3.5% 2,000,000 0.24% $18,800,000
VANGUARD GROUP INC 3.1% 1,781,257 +35% 0% $16,743,815
PRICE T ROWE ASSOCIATES INC /MD/ 3.1% 1,762,617 +17% 0% $16,569,000
ADAGE CAPITAL PARTNERS GP, L.L.C. 2.9% 1,666,666 0.02% $15,666,660
AIGH Capital Management LLC 2.6% 1,500,000 4.2% $14,100,000
MORGAN STANLEY 1.8% 1,002,495 +475% 0% $9,423,453
Insight Holdings Group, LLC 1.7% 989,054 0% 0.7% $9,297,108
Balyasny Asset Management L.P. 1.7% 980,869 0.02% $9,220,169
Woodline Partners LP 1.5% 845,143 +235% 0.03% $7,944,344
Propel Bio Management, LLC 1.2% 666,666 5.4% $6,266,660
MBB PUBLIC MARKETS I LLC 1.1% 614,477 0% 0.6% $5,776,084
Alyeska Investment Group, L.P. 1.1% 600,000 0.02% $5,640,000
MILLENNIUM MANAGEMENT LLC 1% 593,369 +7.6% 0% $5,577,669
BlackRock, Inc. 0.96% 544,539 +13% 0% $5,118,666
D. E. Shaw & Co., Inc. 0.91% 518,512 0% $4,874,013
RFG Advisory, LLC 0.78% 445,200 0.08% $4,184,880
CITADEL ADVISORS LLC 0.48% 275,446 +1459% 0% $2,589,192
HEIGHTS CAPITAL MANAGEMENT, INC 0.48% 271,822 0.97% $2,555,127
GEODE CAPITAL MANAGEMENT, LLC 0.47% 266,402 -4.3% 0% $2,505,726
BNP PARIBAS FINANCIAL MARKETS 0.44% 252,151 0% 0% $2,370,219
SUSQUEHANNA INTERNATIONAL GROUP, LLP 0.42% 238,828 +18% 0% $2,244,983
TD Asset Management Inc 0.39% 222,796 +35% 0% $2,094,282

Institutional Holders of Kyverna Therapeutics, Inc. - Common Stock, par value $0.00001 per share (KYTX) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q1 172,035 $1,484,171 -$2,816,869 $8.63 7
2025 Q4 34,131,760 $320,775,226 +$111,162,333 $9.40 99
2025 Q3 22,688,863 $136,134,153 -$2,158,017 $6.00 74
2025 Q2 23,200,134 $71,227,727 -$5,373,744 $3.07 77
2025 Q1 25,800,890 $49,797,231 -$8,775,592 $1.93 86
2024 Q4 28,863,400 $107,952,189 -$6,920,913 $3.74 87
2024 Q3 28,136,737 $138,294,516 -$28,965,516 $4.89 92
2024 Q2 31,935,411 $239,516,646 -$86,044,405 $7.50 87
2024 Q1 30,688,965 $762,283,849 +$760,773,578 $24.84 88